VYNE Therapeutics Faces Setback in Phase 2b Trial

VYNE Therapeutics shares are trading lower after the company announced that its Phase 2b trial for Repibresib gel in nonsegmental vitiligo failed to meet its primary endpoint, leading to the trial's termination.